ArticleEMBO reports2017
p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Open access · bronzeAbstract read
In one paragraph
Article in EMBO reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.bioRxiv : the preprint server for biology · 2026Article
- CDC7 is a targetable regulator of advanced prostate cancer.Scientific reports · 2025Article
- Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.Nature communications · 2025Article
- Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma.BMC urology · 2025Article
- Synthetic lethal strategies for the development of cancer therapeutics.Nature reviews. Clinical oncology · 2025Review
- CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Development of a novel centrosome-related risk signature to predict prognosis and treatment response in lung adenocarcinoma.Discover oncology · 2024Article
- CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.Signal transduction and targeted therapy · 2024Article
- Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2.BMC cancer · 2024Article
- The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.The Journal of clinical investigation · 2023Article
- MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling.Cell death discovery · 2022Article
- CDC7 as a novel biomarker and druggable target in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- BAP1 phosphorylation-mediated Sp1 stabilization plays a critical role in cathepsin K inhibition-induced C-terminal p53-dependent Bax upregulation.Redox biology · 2022Article
- Disrupted control of origin activation compromises genome integrity upon destabilization of Polε and dysfunction of the TRP53-CDKN1A/P21 axis.Cell reports · 2022Article
- SRSF1 governs progenitor-specific alternative splicing to maintain adult epithelial tissue homeostasis and renewal.Developmental cell · 2022Article
- CDC7 Expression in Selected Odontogenic Tumors.International journal of dentistry · 2022Article
- Upregulated miRNAs on theFrontiers in genetics · 2022Article
- Article
- Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.Frontiers in genetics · 2022Article
- The Function of the Mutant p53-R175H in Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Arindam DattaCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Dishari GhatakCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Sumit DasLaboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science (NCCS), Pune, India.
Taraswi BanerjeeLaboratory of Molecular Gerontology, National Institute on Aging, NIH Biomedical Research Center, NIH, Baltimore, MD, USA.
Anindita PaulDepartment of Biochemistry, University of Calcutta, Kolkata, India.
Ramesh ButtiLaboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science (NCCS), Pune, India.
Mahadeo GorainLaboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science (NCCS), Pune, India.
Sangeeta GhuwalewalaCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Anirban RoychowdhuryDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India.
Sk Kayum AlamCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Pijush DasCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Raghunath ChatterjeeHuman Genetics Unit, Indian Statistical Institute, Kolkata, India.
Maitrayee DasguptaDepartment of Biochemistry, University of Calcutta, Kolkata, India.
Chinmay Kumar PandaDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India.
Gopal C KunduLaboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science (NCCS), Pune, India.
Susanta RoychoudhuryCancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India susantarc@gmail.com.ORCID 0000-0002-4828-7755
Indian Institute of Chemical Biology · INNational Centre for Cell Science · INChittaranjan National Cancer Institute · INUniversity of Calcutta · INIndian Statistical Institute · INNational Institute on Aging · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated p53 missense mutants confer
Indexed as
DNA ReplicationGene Expression Regulation, NeoplasticMutationAdenocarcinomaAdenocarcinoma of LungAnimalsCell Cycle ProteinsCell Line, TumorDNA, NeoplasmGene Expression ProfilingHumansLung NeoplasmsMaleMiceMice, Inbred NODMice, SCIDCDC7 protein, humanCell Cycle ProteinsDBF4 protein, humanDNA, NeoplasmMCM2 protein, humanMinichromosome Maintenance Complex Component 2Protein Serine-Threonine KinasesProto-Oncogene Proteins c-mybRNA, Small InterferingTumor Suppressor Protein p53Cdc7‐Dbf4gain‐of‐functionmutant p53origin firingreplication
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.